Eliglustat GZ385660 ( DrugBank: Eliglustat )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	2

19. ライソゾーム病

---

臨床試験数 : 854 /  薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03485677 (ClinicalTrials.gov)	April 11, 2018	23/3/2018	Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3	Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3	Gaucher's Disease Type I;Gaucher's Disease Type III	Drug: Eliglustat GZ385660;Drug: Imiglucerase GZ437843	Sanofi	NULL	Recruiting	2 Years	17 Years	All	60	Phase 3	Argentina;Canada;France;Italy;Japan;Russian Federation;Spain;Sweden;Turkey;United Kingdom
2	NCT02536755 (ClinicalTrials.gov)	October 28, 2015	27/8/2015	Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease	Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies	Gaucher's Disease	Drug: eliglustat GZ385660	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	All	31	Phase 3	Canada;Russian Federation;Tunisia